CA2532078A1 - Derives de naphtylene constituant des inhibiteurs du cytochrome p450 - Google Patents

Derives de naphtylene constituant des inhibiteurs du cytochrome p450 Download PDF

Info

Publication number
CA2532078A1
CA2532078A1 CA002532078A CA2532078A CA2532078A1 CA 2532078 A1 CA2532078 A1 CA 2532078A1 CA 002532078 A CA002532078 A CA 002532078A CA 2532078 A CA2532078 A CA 2532078A CA 2532078 A1 CA2532078 A1 CA 2532078A1
Authority
CA
Canada
Prior art keywords
10alkyl
10alkynyl
10alkenyl
cycloc3
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002532078A
Other languages
English (en)
Inventor
Vanessa Smith
Anthony Nigro
Mark Mulvihill
Cara Cesario
Patricia Anne Beck
Arlindo Lucas Castelhano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Osi Pharmaceuticals, Inc.
Vanessa Smith
Anthony Nigro
Mark Mulvihill
Cara Cesario
Patricia Anne Beck
Arlindo Lucas Castelhano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals, Inc., Vanessa Smith, Anthony Nigro, Mark Mulvihill, Cara Cesario, Patricia Anne Beck, Arlindo Lucas Castelhano filed Critical Osi Pharmaceuticals, Inc.
Publication of CA2532078A1 publication Critical patent/CA2532078A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
CA002532078A 2003-07-10 2004-07-12 Derives de naphtylene constituant des inhibiteurs du cytochrome p450 Abandoned CA2532078A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
US60/486,382 2003-07-10
PCT/US2004/022282 WO2005007631A1 (fr) 2003-07-10 2004-07-12 Derives de naphtylene constituant des inhibiteurs du cytochrome p450

Publications (1)

Publication Number Publication Date
CA2532078A1 true CA2532078A1 (fr) 2005-01-27

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002532078A Abandoned CA2532078A1 (fr) 2003-07-10 2004-07-12 Derives de naphtylene constituant des inhibiteurs du cytochrome p450

Country Status (15)

Country Link
EP (1) EP1654236A1 (fr)
JP (1) JP4832295B2 (fr)
KR (1) KR20060052799A (fr)
CN (1) CN1819996B (fr)
AU (1) AU2004257257B2 (fr)
BR (1) BRPI0412424A (fr)
CA (1) CA2532078A1 (fr)
IL (1) IL172812A0 (fr)
IS (1) IS8223A (fr)
MX (1) MXPA06000401A (fr)
NO (1) NO20060114L (fr)
RU (1) RU2363696C2 (fr)
SG (1) SG144941A1 (fr)
UA (1) UA87822C2 (fr)
WO (1) WO2005007631A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696899A1 (fr) * 2003-12-17 2006-09-06 Allergan, Inc. Procedes permettant de traiter des troubles sensibles au retinoide au moyen d'inhibiteurs selectifs de cyp26a et de cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US8513291B2 (en) 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
KR20180039185A (ko) * 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EP2651905B1 (fr) * 2010-12-13 2017-07-19 Innocrin Pharmaceuticals, Inc. Composés inhibiteurs de métalloenzyme
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (fr) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions et méthodes de traitement de maladies dysprolifératives
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (fr) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft Dérivés de 2-[2-phényl-1-(sulfonylméthyl)vinyl]-imidazo[4,5-b]pyridine et composés apparentés utilisés comme pesticides en protection des plantes
EP3568395A1 (fr) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Dérivés hétérocycliques utilisés comme pesticides
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物(一)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (fr) * 1960-05-04
NL131915C (fr) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1−置換−1−(1h−イミダゾール−4−イル)メタノール類

Also Published As

Publication number Publication date
CN1819996B (zh) 2010-10-27
RU2363696C2 (ru) 2009-08-10
WO2005007631A1 (fr) 2005-01-27
EP1654236A1 (fr) 2006-05-10
KR20060052799A (ko) 2006-05-19
UA87822C2 (ru) 2009-08-25
JP4832295B2 (ja) 2011-12-07
SG144941A1 (en) 2008-08-28
MXPA06000401A (es) 2006-03-17
AU2004257257B2 (en) 2011-05-12
IL172812A0 (en) 2006-06-11
CN1819996A (zh) 2006-08-16
BRPI0412424A (pt) 2006-09-05
RU2006103996A (ru) 2006-07-10
NO20060114L (no) 2006-02-09
JP2007523866A (ja) 2007-08-23
AU2004257257A1 (en) 2005-01-27
IS8223A (is) 2006-01-10

Similar Documents

Publication Publication Date Title
CA2532078A1 (fr) Derives de naphtylene constituant des inhibiteurs du cytochrome p450
US7994204B2 (en) Binding inhibitor of sphingosine-1-phosphate
AU2012328034B2 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
EP2368887B1 (fr) Dérivés de 1,2,3-triazole destinés à être utilisés comme inhibiteurs de la stéaroyl-coa désaturase
US7662844B2 (en) Naphthylene derivatives as cytochrome P450 inhibitors
AU2008247102A1 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
EP1442034A1 (fr) Derives de benzimidazoles et leur utilisation comme inhibiteurs de proteine kinase kdr
WO2004022523A2 (fr) Derives de promedicaments a base de 1, 3-diamino-2-hydroxypropane
FR2542315A1 (fr) Nouveaux composes azoliques, leur preparation et leur utilisation comme antifongiques et fongicides
CA2126972C (fr) Derive du styrene et ses sels
AU758246B2 (en) N,N-substituted cyclic amine derivatives
KR20010101730A (ko) 매트릭스 금속단백질분해효소 억제제로서의2,3,4,5-테트라하이드로-1에이치-[1,4]벤조디아제핀-3-하이드록삼산
CA2893239A1 (fr) Composes de triazole et d'imidazole substitues
JP3415865B2 (ja) 光学活性アゾール化合物およびその用途
WO1996031491A1 (fr) Agent antifongique de triazole
CZ72095A3 (en) Benzenealkanoic acids as such and for use in medicine, process of their preparation and their use for the preparation of medicaments and pharmaceutical preparations based thereon
CN109195947B (zh) 安眠蛋白α和β的新型抑制剂
KR20030025931A (ko) 2-아미노티아졸린 유도체 및 no-신타제 억제제로서의이의 용도
AU2017224343A1 (en) Novel pyrrolidine derivatives
US7288541B2 (en) Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
WO1998033778A1 (fr) Derives triazole
OA16888A (en) (4-phenylimidazol-2-YL) ethylamine derivatives useful as sodium channel modulators
JPH07291965A (ja) 新規なピロリジン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued